{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:03:33Z","timestamp":1780635813541,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neuropharm.2025.110707","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:36:51Z","timestamp":1760499411000},"page":"110707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The first applications of mescaline in psychiatry: The case of Madame Louise Fran\u00e7oise R. and its contemporary relevance"],"prefix":"10.1016","volume":"282","author":[{"given":"Marion","family":"Hendrickx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4177-8992","authenticated-orcid":false,"given":"Antoine","family":"Dampierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4296-6981","authenticated-orcid":false,"given":"Emmanuel","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110707_bib1","series-title":"Der Meskalinrausch: Seine Geschichte und Erscheinungsweise","author":"Beringer","year":"1927"},{"key":"10.1016\/j.neuropharm.2025.110707_bib2","article-title":"Du Peyotl dans les \u00e9tats anxieux","author":"Briau","year":"1928","journal-title":"Facult\u00e9 de m\u00e9decine de Paris"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110707_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2025.110707_bib4","first-page":"838","article-title":"La mescaline, substance hallucinog\u00e8ne","volume":"115","author":"Claude","year":"1934","journal-title":"Comptes rendus de la Soci\u00e9t\u00e9 de biologie de Paris"},{"issue":"338","key":"10.1016\/j.neuropharm.2025.110707_bib6","first-page":"239","article-title":"Les solutions injectables et la pharmacop\u00e9e fran\u00e7aise","volume":"91","author":"Dauphin","year":"2003","journal-title":"Rev. Hist. Pharm."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110707_bib7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.neurol.2018.11.005","article-title":"Peduncular hallucinosis according to Jean Lhermitte","volume":"175","author":"Drouin","year":"2019","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.neuropharm.2025.110707_bib8","first-page":"36","article-title":"Le traitement m\u00e9diatique du LSD en France en 1966: De la panique morale \u00e0 la fin des \u00e9tudes cliniques","volume":"4","author":"Dubus","year":"2021","journal-title":"Cygne noir"},{"key":"10.1016\/j.neuropharm.2025.110707_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1131565","article-title":"History of the administration of psychedelics in France","volume":"14","author":"Dubus","year":"2023","journal-title":"Front. Psychol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2025.110707_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2005.04.022","article-title":"Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas","volume":"101","author":"El-Seedi","year":"2005","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110707_bib11","first-page":"1","article-title":"Essai d\u2019application des principes de Jackson \u00e0 une conception dynamique de la neuropsychiatrie","volume":"33","author":"Ey","year":"1938","journal-title":"L\u2019Enc\u00e9phale"},{"key":"10.1016\/j.neuropharm.2025.110707_bib12","series-title":"Trait\u00e9 des hallucinations","author":"Ey","year":"1973"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110707_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF01825267","article-title":"Ueber pellote","volume":"40","author":"Heffter","year":"1898","journal-title":"Naunyn-Schmiedeberg\u2019s Archiv f\u00fcr experimentelle Pathologie und Pharmakologie"},{"key":"10.1016\/j.neuropharm.2025.110707_bib14","series-title":"Mescal: the \u201cDivine\u201d Plant and its Psychological Effects","author":"Kl\u00fcver","year":"1928"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110707_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110707_bib16","series-title":"Visions Color\u00e9es Produites par la Mescaline","author":"Marinescu","year":"1933"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110707_bib17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110707_bib18","first-page":"125","article-title":"Contribution \u00e0 la psychopathologie de l\u2019intoxication par la mescaline","volume":"33","author":"Morselli","year":"1936","journal-title":"J. Psychol. Normale Pathol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110707_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110707_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs: a new era in psychiatry?","volume":"21","author":"Nutt","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110707_bib21","series-title":"Convention Sur Les Substances Psychotropes","year":"1971"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110707_bib22","first-page":"56","article-title":"De la posologie des liquides","volume":"26","author":"R\u00e9veil","year":"1861","journal-title":"Bulletin de l\u2019Acad\u00e9mie de M\u00e9decine"},{"key":"10.1016\/j.neuropharm.2025.110707_bib23","series-title":"Le Peyotl: La Plante Qui Fait les Yeux \u00c9merveill\u00e9s","author":"Rouhier","year":"1927"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110707_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110707_bib25","first-page":"245","article-title":"Julius Wagner-Jauregg and the legacy of malarial therapy for the treatment of general paresis of the insane","volume":"86","author":"Tsay","year":"2013","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.neuropharm.2025.110707_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109294","article-title":"Mescaline: the forgotten psychedelic","volume":"222","author":"Vamvakopoulou","year":"2023","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110707_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/archneurpsyc.1932.02240010060004","article-title":"Inconstancy of the formal structure of the personality: experimental study of the influence of mescaline on the Rorschach test","volume":"28","author":"Wertham","year":"1932","journal-title":"Arch. Neurol. Psychiatry (Chic.)"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:28:41Z","timestamp":1780633721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S0028390825004150"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110707","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first applications of mescaline in psychiatry: The case of Madame Louise Fran\u00e7oise R. and its contemporary relevance","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110707"}}